News
Lytix and Curida: Growth and innovation
Lytix Biopharma and Curida, both Norwegian-owned, have gained attention and acclaim for their innovative approaches and substantial contributions to the healthcare sector.
Sammen om superklynge
De fire helseklyngene gikk denne uka sammen om et høringsinnspill til Stortinget.
Results from breast cancer screening pilot
A clinical pilot for personalised risk-based breast cancer screening has been conducted as part of the AnteNOR project. Here are some of the results.
Har partiene en kreftpolitikk?
During the breakfast seminar The Future of Cancer Politics four politicians discussed possible health- and cancer policies in their coming party programmes. The seminar was held in Norwegian.
DoMore Diagnostics secures EUR 10 million grant
In a great achievement, DoMore Diagnostics has been awarded the prestigious EIC Accelerator grant totalling EUR 10 million.
One of Europe’s Leading Start-up Hubs
Oslo Cancer Cluster Incubator made the Financial Times Europe’s Leading Start-up Hubs list.
What does it take to make it?
What does it take to make it for new biotech companies?
Advancing Cancer Research in Norway: Eli Lilly’s SUNRAY-01 Study
Eli Lilly selected Norway as the site for its groundbreaking study project, despite the decline of the recent year's number of clinical cancer trials.
Unique collaboration to build Nordic health industry
A new collaboration agreement between AstraZeneca, Oslo Cancer Cluster, and Oslo Science City aims to strengthen the Nordic health industry.
A peak into Cancer Crosslinks
World-leading translational cancer research entered Oslo Cancer Cluster Innovation Park last week and created a buzz.
Making Cancer Crosslinks possible
Meet the sponsors behind Cancer Crosslinks 2024: Bristol Myers Squibb and Daiichi-Sankyo.
Meet our new members
Meet the members who recently joined or re-joined our cluster.
